CytoSorbents CEO Provides Exclusive Interview With medGadget

CytoSorbents CEO Provides Exclusive Interview With medGadget

Dr. Phillip Chan Discusses the Potential of CytoSorb(R) to Revolutionize
Critical Care Medicine, the Strategy in Europe, and Plans for a US Pivotal

MONMOUTH JUNCTION, N.J., May 1, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care-focused company using blood
purification to treat life-threatening illnesses, announced that medGadget has
published an online exclusive interview with CytoSorbents' Chief Executive
Officer, Dr. Phillip Chan. In the interview, Dr. Chan explains how its unique
CytoSorb® blood filter targets the prevention or treatment of organ failure,
the leading cause of death in the intensive care unit today despite the best
medical treatment.

Topics covered in the interview:

  *How an excessive immune response and the overproduction of cytokines, or
    "cytokine storm," can lead to severe uncontrolled inflammation and failure
    of vital organs in life-threatening illnesses such as sepsis, burn injury,
    trauma, lung injury and many others seen in the intensive care unit (ICU)
  *How ICU doctors currently lack the therapies to prevent or treat
    inflammation and organ failure in critically-ill patients, leading to a
    risk of death that often exceeds 30%, protracted ICU stays at a cost of
    $2,000-3,000 per day in the ICU, and a staggering cost of $80-90 billion
    to the US economy each year
  *A description of CytoSorbents' blood purification technology based upon
    its proprietary biocompatible porous polymer beads covered by 32 issued US
    patents and multiple applications pending and how these beads are packed
    into the CytoSorb® blood filters
  *Why CytoSorb® is unique as the only specifically approved cytokine filter
    in the European Union, how it works,and how it has been clinically proven
    to reduce cytokine storm in critically-ill patients while imparting
    positive clinical benefits including survival, in high risk patients in a
    post-hoc analysis
  *CytoSorbents' progress in selling CytoSorb® via its direct sales force in
    Germany, Austria and Switzerland and the strategy to accelerate revenues
    with sales to distributors or partners in other countries in the European
    Union and those outside the E.U. that will accept European regulatory
  *Plans to conduct a pivotal trial in the US in sepsis, with the goal of
    seeking US regulatory approval for CytoSorb® by the 2016-2017 timeframe
    with positive trial data
  *A brief overview of some additional and exciting blood purification
    applications under development for the porous bead technology including
    HemoDefend, designed to improve the safety and quality of more than 100
    million transfused blood products administered each year, and
    ContrastSorb, designed to prevent IV contrast induced kidney damage in the
    more than 10 million high risk CT scans and interventional radiology
    procedures, such as coronary artery stent placement, each year

The full interview can be found at:

Additional information is available for download on the Company's website:

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein.Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         Valter Pinto
         (914) 669-0222 x201
         Media Contact:
         JQA Partners
         Jules Abraham
         (917) 885-7378
Press spacebar to pause and continue. Press esc to stop.